These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 26912815)
1. A Novel Binding Mode Reveals Two Distinct Classes of NMDA Receptor GluN2B-selective Antagonists. Stroebel D; Buhl DL; Knafels JD; Chanda PK; Green M; Sciabola S; Mony L; Paoletti P; Pandit J Mol Pharmacol; 2016 May; 89(5):541-51. PubMed ID: 26912815 [TBL] [Abstract][Full Text] [Related]
2. Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold. Ritter N; Korff M; Markus A; Schepmann D; Seebohm G; Schreiber JA; Wünsch B Cell Physiol Biochem; 2021 Mar; 55(S3):1-13. PubMed ID: 33656308 [TBL] [Abstract][Full Text] [Related]
3. Exploring the overlapping binding sites of ifenprodil and EVT-101 in GluN2B-containing NMDA receptors using novel chicken embryo forebrain cultures and molecular modeling. Fjelldal MF; Freyd T; Evenseth LM; Sylte I; Ring A; Paulsen RE Pharmacol Res Perspect; 2019 Jun; 7(3):e00480. PubMed ID: 31164987 [TBL] [Abstract][Full Text] [Related]
4. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Karakas E; Simorowski N; Furukawa H Nature; 2011 Jun; 475(7355):249-53. PubMed ID: 21677647 [TBL] [Abstract][Full Text] [Related]
5. Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors. Mony L; Krzaczkowski L; Leonetti M; Le Goff A; Alarcon K; Neyton J; Bertrand HO; Acher F; Paoletti P Mol Pharmacol; 2009 Jan; 75(1):60-74. PubMed ID: 18923063 [TBL] [Abstract][Full Text] [Related]
6. Allosteric regulation in NMDA receptors revealed by the genetically encoded photo-cross-linkers. Tian M; Ye S Sci Rep; 2016 Oct; 6():34751. PubMed ID: 27713495 [TBL] [Abstract][Full Text] [Related]
7. Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators. Burger PB; Yuan H; Karakas E; Geballe M; Furukawa H; Liotta DC; Snyder JP; Traynelis SF Mol Pharmacol; 2012 Aug; 82(2):344-59. PubMed ID: 22596351 [TBL] [Abstract][Full Text] [Related]
8. Structure-guided design of new indoles as negative allosteric modulators (NAMs) of N-methyl-D-aspartate receptor (NMDAR) containing GluN2B subunit. Buemi MR; De Luca L; Ferro S; Russo E; De Sarro G; Gitto R Bioorg Med Chem; 2016 Apr; 24(7):1513-9. PubMed ID: 26912202 [TBL] [Abstract][Full Text] [Related]
9. New advances in NMDA receptor pharmacology. Ogden KK; Traynelis SF Trends Pharmacol Sci; 2011 Dec; 32(12):726-33. PubMed ID: 21996280 [TBL] [Abstract][Full Text] [Related]
10. Structural basis of subunit selectivity for competitive NMDA receptor antagonists with preference for GluN2A over GluN2B subunits. Lind GE; Mou TC; Tamborini L; Pomper MG; De Micheli C; Conti P; Pinto A; Hansen KB Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6942-E6951. PubMed ID: 28760974 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Glutamate Receptor Subunits Reveal the Transmembrane Domain Is Sufficient for NMDA Receptor Pore Properties but Some Positive Allosteric Modulators Require Additional Domains. Wilding TJ; Lopez MN; Huettner JE J Neurosci; 2016 Aug; 36(34):8815-25. PubMed ID: 27559165 [TBL] [Abstract][Full Text] [Related]
12. Synaptic NMDA receptors in basolateral amygdala principal neurons are triheteromeric proteins: physiological role of GluN2B subunits. Delaney AJ; Sedlak PL; Autuori E; Power JM; Sah P J Neurophysiol; 2013 Mar; 109(5):1391-402. PubMed ID: 23221411 [TBL] [Abstract][Full Text] [Related]
13. Activation of NMDA receptors and the mechanism of inhibition by ifenprodil. Tajima N; Karakas E; Grant T; Simorowski N; Diaz-Avalos R; Grigorieff N; Furukawa H Nature; 2016 Jun; 534(7605):63-8. PubMed ID: 27135925 [TBL] [Abstract][Full Text] [Related]
14. Piroxicam inhibits NMDA receptor-mediated excitotoxicity through allosteric inhibition of the GluN2B subunit: an in silico study elucidating a novel mechanism of action of the drug. Mazumder MK; Borah A Med Hypotheses; 2014 Dec; 83(6):740-6. PubMed ID: 25459147 [TBL] [Abstract][Full Text] [Related]
15. A novel family of negative and positive allosteric modulators of NMDA receptors. Costa BM; Irvine MW; Fang G; Eaves RJ; Mayo-Martin MB; Skifter DA; Jane DE; Monaghan DT J Pharmacol Exp Ther; 2010 Dec; 335(3):614-21. PubMed ID: 20858708 [TBL] [Abstract][Full Text] [Related]
16. A conserved structural mechanism of NMDA receptor inhibition: A comparison of ifenprodil and zinc. Sirrieh RE; MacLean DM; Jayaraman V J Gen Physiol; 2015 Aug; 146(2):173-81. PubMed ID: 26170175 [TBL] [Abstract][Full Text] [Related]
17. GluN2A and GluN2B NMDA receptors use distinct allosteric routes. Tian M; Stroebel D; Piot L; David M; Ye S; Paoletti P Nat Commun; 2021 Aug; 12(1):4709. PubMed ID: 34354080 [TBL] [Abstract][Full Text] [Related]
18. Structural changes of regulatory domain heterodimer of N-methyl-D-aspartate receptor subunits GluN1 and GluN2B through the binding of spermine and ifenprodil. Tomitori H; Suganami A; Saiki R; Mizuno S; Yoshizawa Y; Masuko T; Tamura Y; Nishimura K; Toida T; Williams K; Kashiwagi K; Igarashi K J Pharmacol Exp Ther; 2012 Oct; 343(1):82-90. PubMed ID: 22743575 [TBL] [Abstract][Full Text] [Related]
19. Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating. Bhatt JM; Prakash A; Suryavanshi PS; Dravid SM Mol Pharmacol; 2013 Jan; 83(1):9-21. PubMed ID: 23007555 [TBL] [Abstract][Full Text] [Related]
20. A common mechanism allows selective targeting of GluN2B subunit-containing Schreiber JA; Schepmann D; Frehland B; Thum S; Datunashvili M; Budde T; Hollmann M; Strutz-Seebohm N; Wünsch B; Seebohm G Commun Biol; 2019; 2():420. PubMed ID: 31754650 [No Abstract] [Full Text] [Related] [Next] [New Search]